Contributions
Abstract: EP1056
Type: E-Poster Presentation
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
It is well known that the increased incidence of hematological malignancies is mainly caused by the growth of non-Hodgkin's lymphoma and multiple myeloma (MM). MM is the second most commonly diagnosed hematological neoplasm over the world. The indicated annual increase of ММ incidence in the world is 0.7%. MM primarily affects the elderly and is typically diagnosed between the ages of 65-74 years and characterized by severe bone, blood and renal complications, impacting therapy choices and quality of life.
Aims
The aim of the current study was a comprehensive analysis of ММ, i.e., their prevalence, incidence and survival rates in Armenia for the period of 2006-2020.
Methods
The main data source for this study was outpatient and dispensary cards, hospitalization journals, as well as clinical data from the Register of Blood Diseases of the Hematology Center after. prof. R. Yeolyan. This information has been supplemented by the data from National Oncological Centre after V.A. Fanarjyan as well as from death registration service at Ministry of Justice RA. Demographic indicators were derived from the database of Statistical Committee of Armenia. Diagnosis of MM and the definition of the stage were carried out according to the criteria proposed by the International Myeloma Working Group. Survival (OS) was determined by the period between the date of diagnosis and the date of death. Direct method of adjustment was used for elimination of possible influence of changes in age structure of population through passage of fifteen years. The time series data was analyzed using least squares regression analysis.
Results
We analyzed the data of 589 (48.2% female and 51.8 male) patients with MM registered in Armenian Hematology Center of the Ministry of Health of the Republic of Armenia from 2006 to 2020. The median age was 60.6 years (range 31–89). Data analysis showed that during the reported time period the increase of the MM incidence was 1.23 per 100 000 population. In comparison to the results obtained for 1966-1971 and 1998-2004, a significant increase in incidence of MM (about 3.6 and 1.4) was found. The low five-year survival rates were beaten in groups of patients who initially refused therapy and / or were diagnosed already in higher ISS stage for this disease. Among patients receiving therapy, the best survival rates were beaten on MP, VAD protocols and VCD and transplantation. The median survival for ISS stage II disease was 26 months, stage III disease 7 months and stage I disease 20 months. The incidence rates for the MM increased during the analyzed period and male over 60 years old were particularly in the risk group.
Conclusion
In general, the results of treatment in the Armenian population with MM were comparable with the data of the total European cohort. The survival rate was lower in patients with higher ISS stage for this disease and untreated patients. Survival rate seems to be better among younger patients than in older ones even with lower ISS stage of this disease. The MM-related deaths prevailed in the first 5 year of MM therapy. The appropriate monitoring and therapy interventions during the first year of MM treatment are apparently important for the long-term treatment results
Keyword(s): Incidence, Multiple myeloma, Survival
Abstract: EP1056
Type: E-Poster Presentation
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
It is well known that the increased incidence of hematological malignancies is mainly caused by the growth of non-Hodgkin's lymphoma and multiple myeloma (MM). MM is the second most commonly diagnosed hematological neoplasm over the world. The indicated annual increase of ММ incidence in the world is 0.7%. MM primarily affects the elderly and is typically diagnosed between the ages of 65-74 years and characterized by severe bone, blood and renal complications, impacting therapy choices and quality of life.
Aims
The aim of the current study was a comprehensive analysis of ММ, i.e., their prevalence, incidence and survival rates in Armenia for the period of 2006-2020.
Methods
The main data source for this study was outpatient and dispensary cards, hospitalization journals, as well as clinical data from the Register of Blood Diseases of the Hematology Center after. prof. R. Yeolyan. This information has been supplemented by the data from National Oncological Centre after V.A. Fanarjyan as well as from death registration service at Ministry of Justice RA. Demographic indicators were derived from the database of Statistical Committee of Armenia. Diagnosis of MM and the definition of the stage were carried out according to the criteria proposed by the International Myeloma Working Group. Survival (OS) was determined by the period between the date of diagnosis and the date of death. Direct method of adjustment was used for elimination of possible influence of changes in age structure of population through passage of fifteen years. The time series data was analyzed using least squares regression analysis.
Results
We analyzed the data of 589 (48.2% female and 51.8 male) patients with MM registered in Armenian Hematology Center of the Ministry of Health of the Republic of Armenia from 2006 to 2020. The median age was 60.6 years (range 31–89). Data analysis showed that during the reported time period the increase of the MM incidence was 1.23 per 100 000 population. In comparison to the results obtained for 1966-1971 and 1998-2004, a significant increase in incidence of MM (about 3.6 and 1.4) was found. The low five-year survival rates were beaten in groups of patients who initially refused therapy and / or were diagnosed already in higher ISS stage for this disease. Among patients receiving therapy, the best survival rates were beaten on MP, VAD protocols and VCD and transplantation. The median survival for ISS stage II disease was 26 months, stage III disease 7 months and stage I disease 20 months. The incidence rates for the MM increased during the analyzed period and male over 60 years old were particularly in the risk group.
Conclusion
In general, the results of treatment in the Armenian population with MM were comparable with the data of the total European cohort. The survival rate was lower in patients with higher ISS stage for this disease and untreated patients. Survival rate seems to be better among younger patients than in older ones even with lower ISS stage of this disease. The MM-related deaths prevailed in the first 5 year of MM therapy. The appropriate monitoring and therapy interventions during the first year of MM treatment are apparently important for the long-term treatment results
Keyword(s): Incidence, Multiple myeloma, Survival